The EU Has Approved a New Drug Against Pancreatic Cancer.
7 Articles
7 Articles
On Tuesday 17 November, the European Commission gave its green light to the placing on the market of daroxonrasib, a promising treatment for patients with pancreatic cancer. The molecule is not expected to be available in France for several months.
The European Union Commission has granted marketing authorization for Daraxonrasib, a drug used to treat metastatic pancreatic cancer that has spread to various parts of the body. The drug, which underwent an accelerated review process, will be used in adult patients who have previously received at least one other treatment.
Preparation of the report of this evaluation is being speeded up, with its availability scheduled for December, with the aim of facilitating access to the medicinal product throughout the European Union.
The European Commission has given the green light to the marketing of daraxonrasib, marketed under the name 'Rasonque' by Revolution Medicine, to treat patients with metastatic pancreatic adenocarcinoma who have already received at least one previous treatment.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium










